Background: The treatment results of metastatic melanoma are miserable if the tumor has
spread beyond the soft tissue and lung, in particular, if dacarbazine (DTIC)-based therapy …

Malignant melanoma continues to increase in incidence. While early melanoma is highly
curable by surgical means, the prognosis of patients with more advanced lesions and/or …

PURPOSE To evaluate the antitumor activity and toxicity of concurrent biochemotherapy that
uses cisplatin, vinblastine, and docarbazine (DTIC)(CVD) in combination with interferon alfa …

Thirty-four patients with advanced malignant melanoma were treated with recombinant
alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and …

Interferon-alpha and dacarbazine combination is a milestone in the treatment of metastatic
malignant melanoma. Objective response rate ranged from 3% to 25%. Our phase II study …

PURPOSE To evaluate the activity and the toxicity of the combination of cisplatin
(CDDP)/recombinant interleukin-2 (rIL-2) and interferon alfa-2a (IFN alpha) in disseminated …

Following recent reports suggesting that the addition of eimetidine to interferon may
enhance response rates in patients with metastatic malignant melanoma, we have …

[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin,
dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a] …

The combination of chemotherapy and immunotherapy seems to improve response rate in
metastatic melanoma. We investigated the effects on toxicity and immunological effects of a …

Background. Interferon‐α (IFNα) and interleukin‐2 (IL‐2) are active agents against
malignant melanoma. There is, however, no consensus on the optimal dosing schedule of …